Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

contec europe, zl du prat, avenue paul duplaix, 56000, vannes, prancūzija - 2-propilo alkoholis, izopropilo alkoholis, propan-2-olis, izopropanolis - veikliosios medžiagos cas nr.: 67-63-0, eb nr.: 200-661-7, veikliosios medžiagos pavadinimas: 2-propilo alkoholis, izopropilo alkoholis, propan-2-olis, izopropanolis, koncentracija: 62.9% , veiklioji - maisto ir pašarų sritis

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

dechra veterinary products a/s - meloksikamas - priešgaisrinės ir antireumatinės priemonės - dogs; cats - Žodžiu pakaba:Šunys palengvinti uždegimą ir skausmą, ūmus ir lėtinis raumenų ir kaulų sistemos sutrikimai. tirpalas injekcinis:Šunys palengvinti uždegimą ir skausmą, ūmus ir lėtinis raumenų ir kaulų sistemos sutrikimai. pooperacinio skausmo ir uždegimo sumažinimas po ortopedinių ir minkštųjų audinių operacijų. katės. pooperacinio skausmo sumažinimas po ovariohisterektomijos ir smulkiųjų minkštųjų audinių operacijų.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

virbac (prancūzija) - užpilamasis tirpalas - 1 ml yra: eprinomektino - 5,0 mg. - galvijams gydyti, užsikrėtus eprinomektinui jautriais parazitais.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

virbac (prancūzija) - užpilamasis tirpalas - 1 ml yra: deltametrino - 10 mg. - galvijams, užsikrėtusiems utėlėmis, plaukagraužiais ir musėmis, bei avims, užsikrėtusioms erkėmis, utėlėmis ir plaukagraužiais, kraujasiurbėmis musėmis ir mėsmusių lervomis, bei plaukagraužiais ir erkėmis užsikrėtusiems ėriukams vietiškai gydyti ir užsikrėtimo profilaktikai.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidinas - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antinavikiniai vaistai - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

roche registration gmbh - atezolizumabas - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antinavikiniai vaistai - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq kaip monotherapy fluorouracilu ir folino suaugusių pacientų su lokaliai išplitusio arba metastazavusio nsclc po ankstesnės chemoterapijos metu. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq kaip monotherapy fluorouracilu ir folino suaugusių pacientų su lokaliai išplitusio arba metastazavusio nsclc po ankstesnės chemoterapijos metu. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

icg farma, uab - azacitidinas - milteliai injekcinei suspensijai - 25 mg/ml - azacitidine

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

acino ag - klopidogrelis - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitromboziniai vaistai - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.